+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Phosphorodiamidate Morpholino Oligomers Market - Global Forecast 2026-2032- Product Image
Phosphorodiamidate Morpholino Oligomers Market - Global Forecast 2026-2032- Product Image
Sale

Phosphorodiamidate Morpholino Oligomers Market - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6120182
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Phosphorodiamidate Morpholino Oligomers Market is projected to reach USD 207.21 Million in 2026. It is expected to continue growing at a CAGR of 14.18%, reaching USD 463.70 Million by 2032.

Phosphorodiamidate Morpholino Oligomers: Executive Overview

Phosphorodiamidate morpholino oligomers (PMOs) are synthetic antisense molecules designed to bind selected RNA sequences and alter gene expression. Their neutral backbone supports high sequence specificity and resistance to enzymatic degradation, making them relevant to targeted approaches for genetic and infectious diseases. Clinical and regulatory attention has centered on rare disorders, particularly conditions involving exon skipping, while research continues across broader RNA-modulation applications.

From Exon Skipping to Broader RNA Therapeutics

The field is shifting from proof of concept toward more specialized, clinically differentiated applications. Progress depends on improving tissue delivery, cellular uptake, dosing convenience, durability, and patient selection. Regulatory experience with PMO-based therapies is also encouraging more structured development of RNA medicines, although technical challenges remain for organs beyond skeletal muscle and for diseases requiring efficient systemic distribution.

Artificial Intelligence Accelerates Sequence and Development Decisions

Artificial intelligence can support PMO research by analyzing genomic and transcriptomic data, prioritizing target sequences, predicting RNA binding and off-target interactions, and identifying patient subgroups most likely to respond. Machine-learning tools may also assist formulation screening, biomarker interpretation, and trial recruitment. These applications complement rather than replace experimental validation, because sequence activity, delivery, toxicity, and clinical benefit remain dependent on biological systems that require laboratory and clinical evidence.

Regional Insights: Uneven Translation Across Global Research Hubs

North America remains an important center for rare-disease research, clinical development, and regulatory experience with antisense medicines. Europe combines strong academic genetics programs with coordinated research networks and established regulatory pathways. Asia-Pacific offers substantial biomedical capacity, with Japan, China, South Korea, and Australia contributing to translational research and clinical infrastructure. Latin America is increasingly relevant for patient identification and multicenter research but faces uneven access to specialized diagnostics. The Middle East is developing precision-medicine capabilities through selected national programs, while Africa’s principal opportunities involve genomic research, disease characterization, and strengthening clinical and laboratory infrastructure.

Group Insights: Policy Alignment and Research Coordination Matter

ASEAN economies present a mixed landscape in which research capabilities and regulatory readiness vary, making regional coordination valuable for rare-disease studies. BRICS members bring substantial scientific and patient populations, but development environments differ significantly across countries. The European Union benefits from shared scientific and regulatory mechanisms, although reimbursement and implementation remain nationally determined. G7 countries provide deep clinical, academic, and manufacturing capabilities. GCC states are investing in advanced healthcare and genomics, while NATO members collectively represent a broad network of biomedical institutions and regulatory systems that can support collaborative research.

Country Insights: Distinct Capabilities Shape PMO Adoption

The United States has extensive rare-disease clinical expertise and a mature regulatory environment. Canada contributes genomic research and specialized clinical networks. In Europe, France, Germany, Italy, Spain, and the United Kingdom combine academic medicine with varying reimbursement and diagnostic pathways. Japan has strong translational capabilities and experience with advanced therapeutics; China is expanding genomic research, clinical infrastructure, and domestic biopharmaceutical development; and South Korea is strengthening biotechnology and precision-medicine capacity. Australia supports clinical research across geographically dispersed populations. India offers expanding scientific and manufacturing capabilities, while Brazil and Mexico are important Latin American research and care hubs. Russia retains scientific capacity, although international collaboration and access conditions can affect development activity.

Priorities for Leaders: Build Evidence, Delivery Capability, and Access

Industry leaders should prioritize disease areas where molecular targets, natural history, and measurable biomarkers are well characterized. Development plans should pair sequence optimization with delivery research, long-term safety monitoring, and early engagement with regulators and patient organizations. Partnerships with diagnostic laboratories and specialist treatment centers can improve patient identification and trial execution. Leaders should also establish data-governance practices for artificial intelligence, validate computational predictions experimentally, and design access strategies that address specialist administration, follow-up requirements, and regional differences in healthcare infrastructure.

Research Methodology: Evidence-Based Assessment of the PMO Landscape

This executive summary uses a structured review of publicly available scientific, clinical, regulatory, and healthcare-system evidence relevant to phosphorodiamidate morpholino oligomers. The assessment considers molecular characteristics, therapeutic mechanisms, development trends, artificial-intelligence applications, research infrastructure, regulatory context, and geographic capabilities. Regional, group, and country comparisons are qualitative and focus on documented strengths, constraints, and strategic relevance. No market estimates, market shares, forecasts, or company-specific conclusions are used.

Conclusion: Clinical Validation and Delivery Will Define the Next Phase

PMOs occupy an established but technically demanding position within RNA therapeutics. Their strongest demonstrated relevance is in sequence-specific treatment strategies, particularly where exon skipping can address a defined genetic defect. Future progress will depend on extending effective delivery, improving durability and convenience, generating robust long-term evidence, and using computational tools responsibly. Scientific rigor, coordinated diagnostics, and equitable implementation will be central to translating PMO innovation into broader patient benefit.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Phosphorodiamidate Morpholino Oligomers Market, by Application
7.1. Introduction
7.2. Genetic Disorders
7.2.1. Dmd
7.2.2. Sma
7.3. Infectious Diseases
7.3.1. Bacterial Infections
7.3.2. Viral Infections
7.4. Oncology
7.4.1. Breast Cancer
7.4.2. Lung Cancer
8. Phosphorodiamidate Morpholino Oligomers Market, by Delivery Modality
8.1. Introduction
8.2. Lipid Conjugated
8.2.1. Cholesterol
8.2.2. Docosanyl
8.3. Peptide Conjugated
8.3.1. Penetratin
8.3.2. Tat
8.4. Unconjugated
9. Phosphorodiamidate Morpholino Oligomers Market, by End User
9.1. Introduction
9.2. Contract Research Organizations
9.3. Hospitals And Clinics
9.4. Pharmaceuticals And Biotech Companies
9.5. Research Institutes
10. Phosphorodiamidate Morpholino Oligomers Market, by Formulation
10.1. Introduction
10.2. Liquid
10.3. Lyophilized Powder
11. Phosphorodiamidate Morpholino Oligomers Market, by Distribution Channel
11.1. Introduction
11.2. Offline
11.3. Online
12. Phosphorodiamidate Morpholino Oligomers Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Phosphorodiamidate Morpholino Oligomers Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Phosphorodiamidate Morpholino Oligomers Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Aurigene Pharmaceutical Services Pvt. Ltd.
16.2. Aurobindo Pharma Ltd.
16.3. Avidity Biosciences, Inc.
16.4. BioMarin Pharmaceutical Inc.
16.5. Biosynth AG
16.6. BOC Sciences, Inc.
16.7. Creative Biogene Corporation
16.8. Dr. Reddy’s Laboratories Ltd.
16.9. Dyne Therapeutics, Inc.
16.10. Eurofins Genomics, LLC
16.11. Gene Link, Inc.
16.12. Gene Tools, LLC
16.13. GenElixir, Inc.
16.14. Inciton, Inc.
16.15. IntegrateRNA
16.16. Nippon Shinyaku Co., Ltd.
16.17. NS Pharma, Inc.
16.18. Sarepta Therapeutics, Inc.
16.19. Sun Pharmaceutical Industries Ltd.
16.20. Valence Labs, Inc.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Phosphorodiamidate Morpholino Oligomers Market, Years Considered for the Study
FIGURE 2. Global Phosphorodiamidate Morpholino Oligomers Market, Research Design
FIGURE 3. Global Phosphorodiamidate Morpholino Oligomers Market, Research Framework
FIGURE 4. Global Phosphorodiamidate Morpholino Oligomers Market, Data Triangulation
FIGURE 5. Global Phosphorodiamidate Morpholino Oligomers Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2025 vs 2032 (%)
FIGURE 7. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2025 vs 2032 (%)
FIGURE 9. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2025 vs 2032 (%)
FIGURE 11. Global Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2025 vs 2032 (%)
FIGURE 13. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Phosphorodiamidate Morpholino Oligomers Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Phosphorodiamidate Morpholino Oligomers Market Segmentation & Coverage
TABLE 2. Global Phosphorodiamidate Morpholino Oligomers Market Size, 2017-2032 (USD Million)
TABLE 3. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 4. Global Genetic Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Genetic Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Genetic Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Dmd Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Dmd Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Dmd Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Sma Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Sma Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Sma Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Bacterial Infections Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Bacterial Infections Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Bacterial Infections Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Viral Infections Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Viral Infections Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Viral Infections Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 32. Global Lipid Conjugated Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Lipid Conjugated Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Lipid Conjugated Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Cholesterol Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Cholesterol Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Cholesterol Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Docosanyl Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Docosanyl Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Docosanyl Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Peptide Conjugated Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Peptide Conjugated Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Peptide Conjugated Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Penetratin Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Penetratin Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Penetratin Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Tat Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Tat Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Tat Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Unconjugated Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Unconjugated Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Unconjugated Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 54. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Hospitals And Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Hospitals And Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Hospitals And Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Pharmaceuticals And Biotech Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Pharmaceuticals And Biotech Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Pharmaceuticals And Biotech Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 67. Global Liquid Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Liquid Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Liquid Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Lyophilized Powder Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Lyophilized Powder Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Lyophilized Powder Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 74. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Asia-Pacific Phosphorodiamidate Morpholino Oligomers Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Asia-Pacific Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 83. Asia-Pacific Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 84. Asia-Pacific Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 85. Asia-Pacific Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 86. Asia-Pacific Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 87. Asia-Pacific Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 88. Asia-Pacific Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 89. Asia-Pacific Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 90. Asia-Pacific Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 91. Asia-Pacific Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 92. North America Phosphorodiamidate Morpholino Oligomers Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. North America Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 94. North America Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 95. North America Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 96. North America Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 97. North America Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 98. North America Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 99. North America Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 100. North America Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 101. North America Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 102. North America Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 103. Latin America Phosphorodiamidate Morpholino Oligomers Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Latin America Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 105. Latin America Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 106. Latin America Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 107. Latin America Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 108. Latin America Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 109. Latin America Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 110. Latin America Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 111. Latin America Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 112. Latin America Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 113. Latin America Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 114. Europe Phosphorodiamidate Morpholino Oligomers Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Europe Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 116. Europe Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 117. Europe Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 118. Europe Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 119. Europe Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 120. Europe Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 121. Europe Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 122. Europe Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 123. Europe Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 124. Europe Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 125. Middle East Phosphorodiamidate Morpholino Oligomers Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Middle East Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 127. Middle East Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 128. Middle East Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 129. Middle East Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 130. Middle East Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 131. Middle East Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 132. Middle East Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 133. Middle East Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 134. Middle East Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 135. Middle East Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 136. Africa Phosphorodiamidate Morpholino Oligomers Market Size, by Region, 2017-2032 (USD Million)
TABLE 137. Africa Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 138. Africa Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 139. Africa Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 140. Africa Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 141. Africa Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 142. Africa Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 143. Africa Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 144. Africa Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. Africa Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 146. Africa Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 147. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Group, 2017-2032 (USD Million)
TABLE 148. ASEAN Phosphorodiamidate Morpholino Oligomers Market Size, by Group, 2017-2032 (USD Million)
TABLE 149. ASEAN Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 150. ASEAN Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 151. ASEAN Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 152. ASEAN Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 153. ASEAN Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 154. ASEAN Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 155. ASEAN Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 156. ASEAN Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. ASEAN Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 158. ASEAN Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 159. GCC Phosphorodiamidate Morpholino Oligomers Market Size, by Group, 2017-2032 (USD Million)
TABLE 160. GCC Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 161. GCC Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 162. GCC Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 163. GCC Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 164. GCC Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 165. GCC Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 166. GCC Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 167. GCC Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 168. GCC Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 169. GCC Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 170. European Union Phosphorodiamidate Morpholino Oligomers Market Size, by Group, 2017-2032 (USD Million)
TABLE 171. European Union Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 172. European Union Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 173. European Union Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 174. European Union Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 175. European Union Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 176. European Union Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 177. European Union Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 178. European Union Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 179. European Union Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 180. European Union Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 181. BRICS Phosphorodiamidate Morpholino Oligomers Market Size, by Group, 2017-2032 (USD Million)
TABLE 182. BRICS Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 183. BRICS Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 184. BRICS Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 185. BRICS Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 186. BRICS Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 187. BRICS Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 188. BRICS Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 189. BRICS Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. BRICS Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 191. BRICS Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 192. G7 Phosphorodiamidate Morpholino Oligomers Market Size, by Group, 2017-2032 (USD Million)
TABLE 193. G7 Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 194. G7 Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 195. G7 Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 196. G7 Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 197. G7 Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 198. G7 Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 199. G7 Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 200. G7 Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 201. G7 Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 202. G7 Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 203. NATO Phosphorodiamidate Morpholino Oligomers Market Size, by Group, 2017-2032 (USD Million)
TABLE 204. NATO Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 205. NATO Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 206. NATO Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 207. NATO Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 208. NATO Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 209. NATO Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 210. NATO Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 211. NATO Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 212. NATO Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 213. NATO Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 214. Global Phosphorodiamidate Morpholino Oligomers Market Size, by Country, 2017-2032 (USD Million)
TABLE 215. United States Phosphorodiamidate Morpholino Oligomers Market Size, 2017-2032 (USD Million)
TABLE 216. United States Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 217. United States Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 218. United States Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 219. United States Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 220. United States Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 221. United States Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 222. United States Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 223. United States Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 224. United States Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 225. United States Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 226. Canada Phosphorodiamidate Morpholino Oligomers Market Size, 2017-2032 (USD Million)
TABLE 227. Canada Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 228. Canada Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 229. Canada Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 230. Canada Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 231. Canada Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 232. Canada Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 233. Canada Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 234. Canada Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. Canada Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 236. Canada Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 237. Mexico Phosphorodiamidate Morpholino Oligomers Market Size, 2017-2032 (USD Million)
TABLE 238. Mexico Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 239. Mexico Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 240. Mexico Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 241. Mexico Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 242. Mexico Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 243. Mexico Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 244. Mexico Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 245. Mexico Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 246. Mexico Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 247. Mexico Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 248. Brazil Phosphorodiamidate Morpholino Oligomers Market Size, 2017-2032 (USD Million)
TABLE 249. Brazil Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 250. Brazil Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 251. Brazil Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 252. Brazil Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 253. Brazil Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 254. Brazil Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 255. Brazil Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 256. Brazil Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 257. Brazil Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 258. Brazil Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 259. United Kingdom Phosphorodiamidate Morpholino Oligomers Market Size, 2017-2032 (USD Million)
TABLE 260. United Kingdom Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 261. United Kingdom Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 262. United Kingdom Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 263. United Kingdom Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 264. United Kingdom Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 265. United Kingdom Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 266. United Kingdom Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 267. United Kingdom Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 268. United Kingdom Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 269. United Kingdom Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 270. Germany Phosphorodiamidate Morpholino Oligomers Market Size, 2017-2032 (USD Million)
TABLE 271. Germany Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 272. Germany Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 273. Germany Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 274. Germany Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 275. Germany Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 276. Germany Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 277. Germany Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 278. Germany Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 279. Germany Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 280. Germany Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 281. France Phosphorodiamidate Morpholino Oligomers Market Size, 2017-2032 (USD Million)
TABLE 282. France Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 283. France Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 284. France Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 285. France Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 286. France Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 287. France Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 288. France Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 289. France Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 290. France Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 291. France Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 292. Russia Phosphorodiamidate Morpholino Oligomers Market Size, 2017-2032 (USD Million)
TABLE 293. Russia Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 294. Russia Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 295. Russia Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 296. Russia Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 297. Russia Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modality, 2017-2032 (USD Million)
TABLE 298. Russia Phosphorodiamidate Morpholino Oligomers Market Size, by Lipid Conjugated, 2017-2032 (USD Million)
TABLE 299. Russia Phosphorodiamidate Morpholino Oligomers Market Size, by Peptide Conjugated, 2017-2032 (USD Million)
TABLE 300. Russia Phosphorodiamidate Morpholino Oligomers Market Size, by End User, 2017-2032 (USD Million)
TABLE 301. Russia Phosphorodiamidate Morpholino Oligomers Market Size, by Formulation, 2017-2032 (USD Million)
TABLE 302. Russia Phosphorodiamidate Morpholino Oligomers Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 303. Italy Phosphorodiamidate Morpholino Oligomers Market Size, 2017-2032 (USD Million)
TABLE 304. Italy Phosphorodiamidate Morpholino Oligomers Market Size, by Application, 2017-2032 (USD Million)
TABLE 305. Italy Phosphorodiamidate Morpholino Oligomers Market Size, by Genetic Disorders, 2017-2032 (USD Million)
TABLE 306. Italy Phosphorodiamidate Morpholino Oligomers Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 307. Italy Phosphorodiamidate Morpholino Oligomers Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 308. Italy Phosphorodiamidate Morpholino Oligomers Market Size, by Delivery Modalit

Companies Mentioned

  • Aurigene Pharmaceutical Services Pvt. Ltd.
  • Aurobindo Pharma Ltd.
  • Avidity Biosciences, Inc.
  • BioMarin Pharmaceutical Inc.
  • Biosynth AG
  • BOC Sciences, Inc.
  • Creative Biogene Corporation
  • Dr. Reddy’s Laboratories Ltd.
  • Dyne Therapeutics, Inc.
  • Eurofins Genomics, LLC
  • Gene Link, Inc.
  • Gene Tools, LLC
  • GenElixir, Inc.
  • Inciton, Inc.
  • IntegrateRNA
  • Nippon Shinyaku Co., Ltd.
  • NS Pharma, Inc.
  • Sarepta Therapeutics, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Valence Labs, Inc.

Related Topics

Related Reports

PMO Conjugates Market - Global Forecast 2026-2032 - Product Image

PMO Conjugates Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Peptide-PMO Conjugates Market - Global Forecast 2026-2032 - Product Image

Peptide-PMO Conjugates Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Ribonucleic Acid (RNA) Therapy Clinical Trials Market Report 2026 - Product Image

Ribonucleic Acid (RNA) Therapy Clinical Trials Market Report 2026

  • Report
  • 250 Pages
  • Global
From
PMO Conjugate Market Report: Trends, Forecast and Competitive Analysis to 2035 - Product Image

PMO Conjugate Market Report: Trends, Forecast and Competitive Analysis to 2035

  • Report
  • 198 Pages
  • Global
From
Peptide Therapeutics - Global Strategic Business Report - Product Image

Peptide Therapeutics - Global Strategic Business Report

  • Report
  • 486 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.